www.idosr.org
Serunjoji, 2025
©IDOSR PUBLICATIONS
ISSN: 2579-0781

International Digital Organization for Scientific Research
IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 24-30, 2025.
https://doi.org/10.59298/IDOSR/JES/112.2430
IDOSRJES11200000

Nanotechnology-Driven Drug Delivery Systems for Obesity Management

Serunjogi Ruth

Department of Clinical Pharmacy Kampala International University Uganda
Email: ruth.serunjogi@studwc.kiu.ac.ug

ABSTRACT

Obesity is a growing global epidemic, associated with diabetes, cardiovascular disease, cancer, and diminished life expectancy. Pharmacological treatments are often limited by poor bioavailability, low target specificity, and systemic toxicity. Nanotechnology offers innovative drug delivery solutions, improving solubility, stability, biodistribution, and therapeutic precision. Nanocarriers including liposomes, polymeric nanoparticles, dendrimers, micelles, and lipid-based systems have demonstrated potential for encapsulating anti-obesity drugs, nutraceuticals, and genetic material. These advances can enhance efficacy while minimizing adverse effects. This review explores the role of nanotechnology in obesity management, focusing on principles of design, recent advances, clinical translation, challenges, and future perspectives. Nanomedicine holds promise to revolutionize obesity therapy, though safety, manufacturing, and regulatory hurdles must be addressed.

Keywords: Obesity, Nanotechnology, Drug delivery, Nanocarriers, Therapeutics

INTRODUCTION

Obesity has reached epidemic proportions, with more than one billion individuals worldwide classified as obese according to the World Health Organization[1–3]. The condition arises from an imbalance between caloric intake and expenditure, compounded by genetic, behavioral, and environmental factors [4]. Beyond excessive fat accumulation, obesity is a complex metabolic disorder that increases the risk of type 2 diabetes, cardiovascular disease, hypertension, fatty liver disease, osteoarthritis, and certain cancers. Its prevalence continues to rise across age groups, including children and adolescents, creating a major global health crisis with enormous socioeconomic costs[5, 6].

Conventional interventions for obesity include lifestyle modification, pharmacotherapy, and bariatric surgery. Although diet and exercise remain the first-line strategy, long-term adherence is poor [7]. Bariatric surgery is effective but invasive and costly, with associated risks of complications and nutritional deficiencies[6, 8, 9]. Pharmacological approaches are more accessible but remain limited by efficacy and safety concerns. Currently available anti-obesity drugs, such as orlistat, liraglutide, and phentermine-topiramate, offer only modest weight reduction, and their long-term safety remains under scrutiny. Furthermore, promising bioactive molecules derived from natural products, such as polyphenols, flavonoids, and alkaloids, often face barriers of poor solubility, instability in the gastrointestinal tract, rapid metabolism, and poor bioavailability[10–13]. These shortcomings reduce their clinical applicability despite strong preclinical evidence of anti-obesity potential.

Nanotechnology introduces novel opportunities to overcome these challenges. Defined by the manipulation of materials at the nanometer scale, nanotechnology provides unique physicochemical properties that can be harnessed for biomedical applications. In drug delivery, nanocarriers can encapsulate therapeutic agents, shielding them from degradation, enhancing solubility, and extending circulation times[7, 14–16]. Functionalization with targeting ligands or responsive polymers enables site-specific delivery and controlled drug release. These innovations are particularly relevant for obesity management, where drugs often need to act in metabolically active tissues such as adipose tissue, liver, or the central nervous system.

Nanocarriers including liposomes, polymeric nanoparticles, dendrimers, micelles, and lipid nanoparticles have been successfully developed to improve the pharmacokinetics and biodistribution of drugs[17–19]. For example, liposomes provide a biocompatible vesicular system capable of encapsulating both hydrophilic and lipophilic molecules, while polymeric nanoparticles made from biodegradable polymers such as PLGA enable sustained and controlled release. Micelles and solid lipid nanoparticles are effective in solubilizing poorly water-soluble

drugs and increasing oral bioavailability. Dendrimers, with their highly branched structure, allow multiple drug conjugations and precise size control, which are advantageous for targeted therapies.

In obesity research, these nanocarriers have been used to deliver natural bioactive molecules like resveratrol and curcumin, enhancing their bioavailability and therapeutic impact. Other studies have encapsulated conventional drugs such as orlistat to reduce gastrointestinal side effects and improve patient compliance[20–22]. Lipid nanoparticles, particularly those adapted from vaccine technologies, have been explored for gene-silencing approaches using siRNA and miRNA, targeting pathways involved in adipogenesis and lipid metabolism. These approaches highlight the potential of nanotechnology not only to improve existing therapies but also to enable entirely new therapeutic modalities[23–25].

However, while preclinical evidence is encouraging, translation into clinical practice remains limited. Key challenges include ensuring long-term safety, avoiding off-target effects, developing cost-effective large-scale manufacturing processes, and navigating complex regulatory landscapes[26, 27]. Moreover, obesity is a multifactorial disease, and effective treatment may require personalized approaches integrating nanomedicine with genetic profiling, microbiome modulation, and precision nutrition. This review explores the role of nanotechnology in obesity management, structured into five sections. Section 2 outlines the principles and types of nanocarriers applied in obesity research. Section 3 summarizes recent advances and applications in preclinical and clinical studies. Section 4 highlights translational challenges, including safety, biodistribution, and regulation. Section 5 discusses clinical perspectives and integration with existing therapies. Section 6 presents future directions, emphasizing precision medicine and interdisciplinary collaboration. Together, these sections provide a comprehensive overview of nanotechnology-driven drug delivery systems for obesity and their potential to transform therapeutic outcomes.

2. Principles of Nanotechnology in Drug Delivery

The application of nanotechnology in drug delivery is based on improving the pharmacokinetics and pharmacodynamics of therapeutic agents. In obesity, drugs and bioactive compounds often face problems such as low water solubility, poor intestinal absorption, rapid metabolism, and systemic side effects[14, 28, 29]. Nanocarriers are designed to overcome these barriers by altering the way drugs are transported and released in the body. By encapsulating molecules within nanoscale systems, it is possible to protect them from degradation, extend circulation time, and deliver them more effectively to target tissues. Liposomes are among the earliest and most widely studied nanocarriers. Composed of phospholipid bilayers, they can encapsulate both hydrophilic and lipophilic drugs, making them versatile. Their surface can be modified with ligands such as antibodies or peptides to achieve active targeting of tissues like adipose depots or the hypothalamus, which are central to obesity regulation. Polymeric nanoparticles, usually made of biodegradable materials such as polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PLGA), allow for controlled release and enhanced stability. This is especially useful for compounds like resveratrol or curcumin, whose bioactivity is otherwise compromised by rapid degradation[30–32].

Dendrimers represent another category of nanocarriers characterized by highly branched three-dimensional structures[33–35]. Their large surface area allows multiple drug molecules or targeting moieties to be attached simultaneously. This property makes dendrimers suitable for multimodal therapy, where a single carrier could deliver both appetite-suppressing drugs and anti-inflammatory molecules. Micelles and solid lipid nanoparticles are also used widely to improve the solubility of poorly water-soluble molecules[25, 27, 36]. They have shown success in enhancing the oral absorption of natural anti-obesity agents, which often fail to reach therapeutic levels in plasma when administered in conventional formulations.

A promising innovation is stimuli-responsive nanocarriers, which release their therapeutic load in response to specific physiological triggers such as pH, enzymes, or temperature changes. For obesity, these could be designed to release drugs selectively in adipose tissues or in the gastrointestinal tract during digestion, thereby reducing unwanted systemic exposure[37, 38]. Surface functionalization also enables nanocarriers to recognize cell-specific receptors, such as those found on adipocytes, facilitating more precise delivery. Together, these principles demonstrate how nanotechnology modifies drug delivery in obesity management. By enhancing solubility, stability, targeting, and controlled release, nanocarriers provide a foundation for more effective pharmacological strategies against obesity.

3. Advances in Nanotechnology for Obesity

Preclinical research has revealed significant advances in the application of nanocarriers for obesity management. Natural bioactive compounds such as polyphenols, flavonoids, and alkaloids are widely studied for their anti-obesity effects[39]. However, their therapeutic potential is often limited by instability in the gastrointestinal tract and low systemic absorption. Encapsulation into nanoparticles has transformed these molecules into more effective agents. For instance, curcumin-loaded polymeric nanoparticles exhibit enhanced bioavailability, prolonged circulation, and improved anti-adipogenic effects compared to free curcumin. Similarly, resveratrol-loaded nanoparticles accumulate more effectively in adipose tissue and lead to greater reductions in fat mass in animal studies[40]. Conventional drugs have also been reformulated using nanotechnology. Orlistat, a pancreatic lipase inhibitor, is well known for its gastrointestinal side effects, which reduce compliance.

Encapsulation in solid lipid nanoparticles has been shown to reduce these adverse effects while maintaining therapeutic efficacy. Appetite-suppressing drugs, which act in the central nervous system, have been delivered using nanocarriers capable of crossing the blood–brain barrier, overcoming one of the major limitations of conventional formulations[41].

Another promising development is the use of nanotechnology for nucleic acid delivery. Small interfering RNA (siRNA) and microRNA (miRNA) therapies can target genes directly involved in adipogenesis, lipid metabolism, or energy expenditure. Lipid nanoparticles already proven successful in mRNA vaccine delivery have been repurposed in obesity research for gene-silencing strategies[42]. Animal models treated with such therapies demonstrate significant weight loss and metabolic improvements, suggesting a new frontier for nanomedicine in obesity. Multi-drug delivery is also an emerging approach. Nanocarriers can co-encapsulate different molecules, such as an appetite suppressant and an anti-inflammatory agent, providing synergistic effects[42]. This is particularly relevant for obesity, which involves multiple pathological mechanisms including inflammation, insulin resistance, and altered lipid metabolism. By targeting more than one pathway simultaneously, nanotechnology could offer more effective interventions than single-agent therapies.

Although most of these studies are preclinical, they demonstrate the versatility and power of nanocarriers to improve drug performance. The advances made so far provide a strong foundation for translating nanotechnology-based obesity therapies into clinical practice, though significant challenges remain.

4. Translational Challenges

Despite promising preclinical data, translating nanotechnology-based therapies into clinical practice for obesity faces numerous obstacles. One of the foremost concerns is safety. Nanoparticles, depending on their size, charge, and composition, can accumulate in non-target organs such as the liver, spleen, or kidneys, potentially causing long-term toxicity. The immune system may recognize nanoparticles as foreign, leading to rapid clearance or unintended inflammatory responses[43]. These risks must be carefully evaluated through long-term toxicological studies before clinical application.

Another significant barrier is manufacturing. Producing nanocarriers with consistent size, drug loading, and release profiles on an industrial scale is technically demanding and costly. Even small variations can affect performance, making reproducibility a major issue. Regulatory agencies require stringent quality control and detailed characterization of nanomedicines, which adds to the complexity of clinical translation[44]. Regulatory hurdles are also pronounced because nanocarriers often act both as drug and device. As such, they are subject to hybrid evaluation criteria, requiring data not only on pharmacokinetics and efficacy but also on material biocompatibility, stability, and long-term safety. This increases the time and cost required for approval. For obesity-specific therapies, where long-term use is likely, safety requirements are especially rigorous.

Obesity itself poses unique challenges. It is a multifactorial disease influenced by genetics, environment, microbiota, and lifestyle [45]. As such, therapeutic responses to nanomedicine may vary widely between patients. A formulation effective in one subgroup may not produce the same outcomes in others. This variability complicates clinical trial design and necessitates a more personalized approach[44]. Economic considerations cannot be overlooked. The high cost of nanomedicine development and manufacturing may limit accessibility, particularly in low-resource settings where obesity prevalence is also high. Unless cost-effectiveness is demonstrated, widespread adoption of nanotechnology-based therapies will remain limited.

Addressing these translational challenges requires multidisciplinary collaboration. Advances in scalable manufacturing, harmonization of regulatory frameworks, and incorporation of patient stratification strategies will be key to moving nanotechnology-driven obesity therapies closer to the clinic.

5. Clinical Perspectives

Although nanotechnology-driven therapies for obesity are not yet in widespread clinical use, lessons can be drawn from other fields where nanomedicine has already been successfully applied. Liposomal doxorubicin and lipid nanoparticle-based mRNA vaccines demonstrate that nanotechnology can be both safe and effective in humans. These successes offer a roadmap for adapting similar strategies to obesity[46].

In clinical research, only a few nanotechnology-based formulations targeting obesity are in early trial stages. For example, nano-encapsulated orlistat and curcumin formulations have shown improved tolerability and bioavailability in human pilot studies. However, robust large-scale clinical trials are lacking, and more evidence is needed to confirm their therapeutic benefits in diverse patient populations. Integration with existing therapies provides another pathway forward[47]. Nanocarriers could be used to enhance the effectiveness of GLP-1 receptor agonists, which are now widely prescribed for obesity and type 2 diabetes. Similarly, nanoparticle formulations could be combined with bariatric surgery or structured lifestyle interventions to maximize long-term outcomes while minimizing drug dosage and side effects.

Personalized medicine approaches are also relevant in clinical contexts[47]. With advances in genomics and metabolomics, it is increasingly possible to stratify patients based on biological markers [48]. Nanocarriers designed for precision delivery could complement such personalized strategies, ensuring that therapies are tailored to individual patient profiles. Despite the promise, the clinical outlook remains cautious[47]. Regulatory agencies emphasize the need for long-term safety data, particularly since obesity therapies are

intended for chronic use. Public acceptance is another factor, as concerns about nanoparticles in food and medicine remain prevalent. Transparent communication and education will be essential to gain trust and facilitate adoption.

Overall, clinical perspectives on nanotechnology in obesity management are optimistic but tempered by the recognition that significant validation through trials, safety studies, and cost-effectiveness analyses is still required.

6. Future Directions

The future of nanotechnology in obesity management lies in its integration with precision medicine and emerging technologies. Artificial intelligence and machine learning are increasingly being applied to nanoparticle design, enabling predictive modeling of pharmacokinetics, biodistribution, and therapeutic efficacy. This computational approach accelerates the optimization of formulations, reducing reliance on trial-and-error experimentation.

Stimuli-responsive systems are another frontier. Carriers that release drugs in response to pH changes, enzymatic activity, or metabolic cues can ensure localized delivery and reduce systemic exposure. Such innovations could allow drugs to be released specifically in adipose tissues or during digestion, maximizing effectiveness while reducing side effects. Hybrid systems capable of carrying multiple drugs or combining pharmacological and genetic therapies in a single carrier may further enhance outcomes.

Personalized nanomedicine will play a major role in future obesity therapies. By integrating patient-specific genomic, proteomic, and metabolomic data, it will be possible to design nanocarriers tailored to individual biological profiles. This could allow stratification of patients into subgroups that benefit most from specific nanoformulations, improving therapeutic outcomes and cost-effectiveness.

Another promising avenue is the delivery of microbiome-modulating agents using nanotechnology. Since gut microbiota plays a critical role in obesity, nanoparticles could be employed to deliver probiotics, prebiotics, or microbiota-targeted drugs directly to the gut in a controlled manner. This represents a novel strategy for addressing obesity at its microbial root.

Finally, collaboration across disciplines will be essential. Nanotechnologists, clinicians, nutritionists, and policymakers must work together to address technical, clinical, and regulatory challenges. Global harmonization of regulatory standards and continued investment in nanomedicine research will help accelerate translation from laboratory to clinic.

If these efforts succeed, nanotechnology has the potential to revolutionize obesity management, transforming it from a largely symptomatic approach to a precise, targeted, and personalized therapeutic field.

CONCLUSION

Nanotechnology-driven drug delivery systems offer innovative solutions to the long-standing challenges of obesity management. By improving drug solubility, stability, and specificity, nanocarriers enhance the therapeutic potential of conventional drugs and natural bioactives. Although translation remains limited by safety, regulatory, and economic challenges, the integration of nanotechnology with precision medicine and advanced computational tools holds great promise for the future.

REFERENCES

1. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metab. Open. 27, 100375 (2025). https://doi.org/10.1016/j.metop.2025.100375
2. Akter, R., Awais, M., Boopathi, V., Ahn, J.C., Yang, D.C., Kang, S.C., Yang, D.U., Jung, S.-K.: Inversion of the Warburg Effect: Unraveling the Metabolic Nexus between Obesity and Cancer. ACS Pharmacol. Transl. Sci. 7, 560 (2024). https://doi.org/10.1021/acsptsci.3c00301
3. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
4. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
6. Behrooz, A.B., Cordani, M., Fiore, A., Donadelli, M., Gordon, J.W., Klionsky, D.J., Ghavami, S.: The obesity-autophagy-cancer axis: Mechanistic insights and therapeutic perspectives. Semin. Cancer Biol. 99, 24–44 (2024). https://doi.org/10.1016/j.semcancer.2024.01.003
7. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0

8. Bhardwaj, P., Au, C.C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., Brown, K.A.: Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J. Steroid Biochem. Mol. Biol. 189, 161–170 (2019). https://doi.org/10.1016/j.jsbmb.2019.03.002
9. Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., Mantzoros, C.S.: Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 58, (2023). https://doi.org/10.1016/j.eclinm.2023.101882
10. Ahmad, R., AlLehaibi, L.H., AlSuwaidan, H.N., Alghiryafi, A.F., Almubarak, L.S., AlKhalifah, K.N., AlMubarak, H.J., Alkhathami, M.A.: Evaluation of clinical trials for natural products used in diabetes. Medicine (Baltimore). 100, e25641 (2021). https://doi.org/10.1097/MD.0000000000025641
11. Ali Abdalla, Y.O., Subramaniam, B., Nyamathulla, S., Shamsuddin, N., Arshad, N.M., Mun, K.S., Awang, K., Nagoor, N.H.: Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade. J. Trop. Med. 2022, 5794350 (2022). https://doi.org/10.1155/2022/5794350
12. Caesar, L.K., Montaser, R., Keller, N.P., Kelleher, N.L.: Metabolomics and Genomics in Natural Products Research: Complementary Tools for Targeting New Chemical Entities. Nat. Prod. Rep. 38, 2041–2065 (2021). https://doi.org/10.1039/d1np00036e
13. Cai, T., Song, X., Xu, X., Dong, L., Liang, S., Xin, M., Huang, Y., Zhu, L., Li, T., Wang, X., Fang, Y., Xu, Z., Wang, C., Wang, M., Li, J., Zheng, Y., Sun, W., Li, L.: Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota. Front. Cell. Infect. Microbiol. 14, 1323261 (2024). https://doi.org/10.3389/fcimb.2024.1323261
14. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B.H., Anjum, I.: Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. Pharmaceuticals. 14, 707 (2021). https://doi.org/10.3390/ph14080707
15. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
16. Bishoyi, A.K., Nouri, S., Hussen, A., Bayani, A., Khaksari, M.N., Soleimani Samarkhazan, H.: Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin. Exp. Med. 25, 166 (2025). https://doi.org/10.1007/s10238-025-01686-z
17. Magadani, R., Ndinteh, D.T., Roux, S., Nangah, L.P., Atangwho, I.J., Uti, D.E., Alum, E.U., Egba, S.I.: Cytotoxic Effects of Lecaniodiscus Cupanioides (Planch.) Extract and Triterpenoids-derived Gold Nanoparticles On MCF-7 Breast Cancer Cell Lines. Anti-Cancer Agents Med. Chem. Former. Curr. Med. Chem. - Anti-Cancer Agents. 25, 841–850 (2025). https://doi.org/10.2174/0118715206325529241004064307
18. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
19. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
20. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
21. Bozzer, S., Dal Bo, M., Grimaldi, M.C., Toffoli, G., Macor, P.: Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies. Pharmaceutics. 14, 1965 (2022). https://doi.org/10.3390/pharmaceutics14091965
22. Milewska, S., Niemirowicz-Laskowska, K., Siemiaszko, G., Nowicki, P., Wilczewska, A.Z., Car, H.: Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. Int. J. Nanomedicine. 16, 6593–6644 (2021). https://doi.org/10.2147/IJN.S323831
23. Wang, X., Tian, Z., Wang, M., Cai, X., Yang, S., Zeng, J., Fang, Y., Bai, X., Wang, P., Sun, Y., Guo, C., Liu, T., Qian, Q.: Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines. J. Transl. Med. 23, 893 (2025). https://doi.org/10.1186/s12967-025-06924-2

24. Gajbhiye, K.R., Salve, R., Narwade, M., Sheikh, A., Kesharwani, P., Gajbhiye, V.: Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol. Cancer. 22, 160 (2023). https://doi.org/10.1186/s12943-023-01849-0
25. Greco, G., Agafonova, A., Cosentino, A., Cardullo, N., Muccilli, V., Puglia, C., Anfuso, C.D., Sarpietro, M.G., Lupo, G.: Solid Lipid Nanoparticles Encapsulating a Benzoxanthene Derivative in a Model of the Human Blood–Brain Barrier: Modulation of Angiogenic Parameters and Inflammation in Vascular Endothelial Growth Factor-Stimulated Angiogenesis. Molecules. 29, 3103 (2024). https://doi.org/10.3390/molecules29133103
26. Niculescu, A.-G., Bîrcă, A.C., Grumezescu, A.M.: New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery. Pharmaceutics. 13, 2053 (2021). https://doi.org/10.3390/pharmaceutics13122053
27. Wang, W., Zhou, M., Xu, Y., Peng, W., Zhang, S., Li, R., Zhang, H., Zhang, H., Cheng, S., Wang, Y., Wei, X., Yue, C., Yang, Q., Chen, C.: Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study. Front. Bioeng. Biotechnol. 9, 762489 (2021). https://doi.org/10.3389/fbioe.2021.762489
28. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
29. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
30. Kapalatiya, H., Madav, Y., Tambe, V.S., Wairkar, S.: Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview. Drug Deliv. Transl. Res. 12, 1293–1305 (2022). https://doi.org/10.1007/s13346-021-01020-6
31. Liu, X., He, F., Liu, M.: New opportunities of stimulus-responsive smart nanocarriers in cancer therapy. Nano Mater. Sci. (2024). https://doi.org/10.1016/j.nanoms.2024.10.013
32. Liu, J., Wang, T., Dong, J., Lu, Y.: The blood–brain barriers: novel nanocarriers for central nervous system diseases. J. Nanobiotechnology. 23, 146 (2025). https://doi.org/10.1186/s12951-025-03247-8
33. Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J.E.N., Hamblin, M.R.: PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl. Mater. Today. 12, 177–190 (2018). https://doi.org/10.1016/j.apmt.2018.05.002
34. Alamos-Musre, S., Beltrán-Chacana, D., Moyano, J., Márquez-Miranda, V., Duarte, Y., Miranda-Rojas, S., Olguín, Y., Fuentes, J.A., González-Nilo, D., Otero, M.C.: From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications. Pharmaceutics. 17, 927 (2025). https://doi.org/10.3390/pharmaceutics17070927
35. Pérez-Ferreiro, M., M. Abelairas, A., Criado, A., Gómez, I.J., Mosquera, J.: Dendrimers: Exploring Their Wide Structural Variety and Applications. Polymers. 15, 4369 (2023). https://doi.org/10.3390/polym15224369
36. Aslam, R., Tiwari, V., Upadhyay, P., Tiwari, A.: REVOLUTIONIZING THERAPEUTIC DELIVERY: DIOSGENIN-LOADED SOLID LIPID NANOPARTICLES UNLEASH ADVANCED CARRIERS. Int. J. Appl. Pharm. 124–133 (2024). https://doi.org/10.22159/ijap.2024v16i1.49306
37. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., Kyzas, G.Z.: Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers. 12, 1397 (2020). https://doi.org/10.3390/polym12061397
38. Majumder, J., Minko, T.: Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin. Drug Deliv. 18, 205–227 (2021). https://doi.org/10.1080/17425247.2021.1828339
39. Parvin, N., Aslam, M., Joo, S.W., Mandal, T.K.: Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. Molecules. 30, 3177 (2025). https://doi.org/10.3390/molecules30153177
40. Yavarpour-Bali, H., Ghasemi-Kasman, M., Pirzadeh, M.: Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomedicine. 14, 4449–4460 (2019). https://doi.org/10.2147/IJN.S208332
41. Xie, P., Shao, T., Long, Y., Xie, W., Liu, Y., Yang, Y., Huang, Y., Wu, R., Deng, Q., Tang, H.: Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial. Lipids Health Dis. 23, 225 (2024). https://doi.org/10.1186/s12944-024-02214-w

42. Weng, Y., Huang, Q., Li, C., Yang, Y., Wang, X., Yu, J., Huang, Y., Liang, X.-J.: Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. Mol. Ther. Nucleic Acids. 19, 581–601 (2019). https://doi.org/10.1016/j.omtn.2019.12.004
43. Desai, N.: Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 14, 282–295 (2012). https://doi.org/10.1208/s12248-012-9339-4
44. Kara, A., Ongoren, B., Anaya, B.J., Lalatsa, A., Serrano, D.R.: Continuous manufacturing of nanomedicines using 3D-printed microfluidic devices. Appl. Mater. Today. 43, 102672 (2025). https://doi.org/10.1016/j.apmt.2025.102672
45. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
46. Tenchov, R., Hughes, K.J., Ganesan, M., Iyer, K.A., Ralhan, K., Lotti Diaz, L.M., Bird, R.E., Ivanov, J.M., Zhou, Q.A.: Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery. ACS Nano. 19, 4011–4038 (2025). https://doi.org/10.1021/acsnano.4c09566
47. Chen, Y., Lu, Y., Lee, R.J., Xiang, G.: Nano Encapsulated Curcumin: And Its Potential for Biomedical Applications. Int. J. Nanomedicine. 15, 3099–3120 (2020). https://doi.org/10.2147/IJN.S210320
48. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622

CITE AS: Serunjogi Ruth (2025). Nanotechnology-Driven Drug Delivery Systems for Obesity Management. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 24-30. https://doi.org/10.59298/IDOSR/JES/112.2430